

**FireGate Biotech Inc.**  
**FOR IMMEDIATE RELEASE**

## **FireGate Biotech Provides January 2026 Research Update**

**Washington, DC — January 9, 2026** — FireGate Biotech Inc. today shared a brief update outlining progress as the company enters 2026. The update includes publication of a computational dataset in Harvard Dataverse and continued preparation for research grant submissions supporting programs FG-001, FG-002, and FG-003.

FireGate Biotech is developing modular research programs designed to explore coordinated immune signaling strategies across infectious disease, oncology, and neuro-immune repair.

### **Acknowledgments**

FireGate would like to thank the principal investigators supporting each program for their scientific leadership, as well as advisors and collaborators who have helped shape the company’s early research infrastructure. The company also appreciates guidance provided by NIH program staff as FireGate evaluates potential funding mechanisms aligned with its research programs.

### **2026 Research Planning**

As FireGate enters 2026, the company plans to submit multiple research grant applications supporting structured program development and early preclinical execution. In parallel, FireGate continues identifying contract research organizations (CROs) aligned with each program’s scientific objectives.

### **Open Science and Data Release**

To support transparency and reproducibility, FireGate has released a computational dataset through Harvard Dataverse:

- **Structural Modeling Assessment of CCR5–PD-L1–bNAb Triplet Geometry** Harvard Dataverse DOI:10.7910/DVN/YEZWKF

This dataset supports computational analysis related to immune signaling pathways explored within the FireGate research framework.

### **About FireGate Biotech Inc.**

FireGate Biotech Inc. is a veteran-founded biotechnology company developing modular, triplet-directed research programs across three initiatives:

- **FG-001** — HIV
- **FG-002** — Oncology viral mimicry
- **FG-003** — Neuro-immune repair

The company’s research platform explores coordinated immune signaling strategies across infectious disease, oncology, and neuro-immune biology.

### **Media Contact**

FireGate Biotech Inc.

<https://firegatebiotech.com>